DeepMed Research

UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasm

Interventions: Drug: Docetaxel
Drug: Vinorelbine
Drug: Filgrastim

First Posted Date: 2005-09-19

Last Posted Date: 2007-12-06

Lead Sponsor: University of Washington

Target Recruit Count: 48

Registration Number: NCT00194740

Locations: 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Soft Tissue Sarcoma

Interventions: Drug: Temozolomide

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-14

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT00194766

Locations: 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States

Telehealth for Diabetes Self-Management

Not Applicable

Completed

Conditions: Diabetes
Aging

Interventions: Other: Telehealth for Diabetes Self Management

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-14

Lead Sponsor: University of Washington

Target Recruit Count: 62

Registration Number: NCT00194805

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Botox as a Treatment for Chronic Male Pelvic Pain Syndrome

Phase 4

Terminated

Conditions: Chronic Male Pelvic Pain Syndrome

First Posted Date: 2005-09-19

Last Posted Date: 2007-10-19

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT00194623

Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-09-19

Last Posted Date: 2006-04-14

Lead Sponsor: University of Washington

Target Recruit Count: 82

Registration Number: NCT00194506

Locations: 🇺🇸
University of Washington, General Internal Medicine Clinic, Roosevelt, Seattle, Washington, United States

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

Phase 4

Completed

Conditions: Contraception

Interventions: Drug: Miglustat (Zavesca)

First Posted Date: 2005-09-19

Last Posted Date: 2008-09-19

Lead Sponsor: University of Washington

Target Recruit Count: 8

Registration Number: NCT00194649

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Childhood Chronic Illness: An Educational Program for Parents of Children With On-Going Health Care Needs

Not Applicable

Completed

Conditions: Chronic Illness

Interventions: Behavioral: 7 week Building on Family Strengths Program

First Posted Date: 2005-09-19

Last Posted Date: 2008-09-29

Lead Sponsor: University of Washington

Target Recruit Count: 129

Registration Number: NCT00194584

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
HER2-positive Breast Cancer
Stage IIIA Breast Cancer
Stage II Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: paclitaxel
Biological: filgrastim
Drug: capecitabine
Drug: methotrexate
Drug: vinorelbine tartrate
Procedure: needle biopsy
Procedure: therapeutic conventional surgery
Other: immunohistochemistry staining method
Biological: trastuzumab
Drug: tamoxifen citrate
Drug: letrozole
Other: laboratory biomarker analysis

First Posted Date: 2005-09-19

Last Posted Date: 2018-03-12

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT00194779

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Phase 1

Completed

Conditions: Stage IV Breast Cancer
HER2/Neu Positive
HLA-A2 Positive Cells Present
Stage IV Ovarian Cancer

Interventions: Biological: HER-2/neu Peptide Vaccine
Other: Laboratory Biomarker Analysis

First Posted Date: 2005-09-19

Last Posted Date: 2024-06-06

Lead Sponsor: University of Washington

Target Recruit Count: 22

Registration Number: NCT00194714

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2016-05-20

Lead Sponsor: University of Washington

Target Recruit Count: 181

Registration Number: NCT00194571

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy